Do analysts rate DSY or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Big Tree Cloud 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, DSY or DRMA?

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Big Tree Cloud $2.02M 9.29 -$32.53M N/A N/A Dermata Therapeutics N/A N/A -$7.56M -$4.39 N/A

Is DSY or DRMA more profitable?

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Big Tree Cloud N/A N/A N/A Dermata Therapeutics N/A -166.66% -130.13%

Does the media prefer DSY or DRMA?

In the previous week, Big Tree Cloud and Big Tree Cloud both had 3 articles in the media. Big Tree Cloud's average media sentiment score of 0.56 beat Dermata Therapeutics' score of 0.47 indicating that Big Tree Cloud is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Big Tree Cloud 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dermata Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DRMA or NHTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Health Trends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DRMA or NHTC?

In the previous week, Dermata Therapeutics had 1 more articles in the media than Natural Health Trends. MarketBeat recorded 3 mentions for Dermata Therapeutics and 2 mentions for Natural Health Trends. Natural Health Trends' average media sentiment score of 1.66 beat Dermata Therapeutics' score of 0.47 indicating that Natural Health Trends is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dermata Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Natural Health Trends 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate NAII or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend MTEX or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ATPC or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agape ATP 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Dermata Therapeutics (DRMA) Competitors

$1.34 -0.12 (-8.22%)

As of 08/28/2026 04:00 PM Eastern

Compare

DRMA vs. DSY, NHTC, NAII, MTEX, and ATPC

Should you buy Dermata Therapeutics stock or one of its competitors? Dermata Therapeutics's main competitors and comparable companies include Big Tree Cloud (DSY), Natural Health Trends (NHTC), Natural Alternatives International (NAII), Mannatech (MTEX), and Agape ATP (ATPC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Big Tree Cloud (NASDAQ:DSY) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Big Tree Cloud and Big Tree Cloud both had 3 articles in the media. Big Tree Cloud's average media sentiment score of 0.56 beat Dermata Therapeutics' score of 0.47 indicating that Big Tree Cloud is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Big Tree Cloud	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dermata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Big Tree Cloud	N/A	N/A	N/A
Dermata Therapeutics	N/A	-166.66%	-130.13%

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Tree Cloud	$2.02M	9.29	-$32.53M	N/A	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

60.2% of Big Tree Cloud shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 34.1% of Big Tree Cloud shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Tree Cloud	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Big Tree Cloud has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Big Tree Cloud beats Dermata Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Health Trends?

Dermata Therapeutics (NASDAQ:DRMA) and Natural Health Trends (NASDAQ:NHTC) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Dermata Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Natural Health Trends has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Natural Health Trends has higher revenue and earnings than Dermata Therapeutics. Natural Health Trends is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Natural Health Trends	$36.04M	0.38	-$880K	-$0.16	N/A

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Natural Health Trends shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 12.9% of Natural Health Trends shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Dermata Therapeutics had 1 more articles in the media than Natural Health Trends. MarketBeat recorded 3 mentions for Dermata Therapeutics and 2 mentions for Natural Health Trends. Natural Health Trends' average media sentiment score of 1.66 beat Dermata Therapeutics' score of 0.47 indicating that Natural Health Trends is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dermata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natural Health Trends	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Health Trends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dermata Therapeutics has a net margin of 0.00% compared to Natural Health Trends' net margin of -4.51%. Natural Health Trends' return on equity of -8.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Natural Health Trends	-4.51%	-8.00%	-4.58%

Summary

Natural Health Trends beats Dermata Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Natural Alternatives International has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

In the previous week, Dermata Therapeutics had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 3 mentions for Dermata Therapeutics and 2 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.95 beat Dermata Therapeutics' score of 0.47 indicating that Natural Alternatives International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dermata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dermata Therapeutics has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.10	-$13.57M	-$2.39	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

Dermata Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Summary

Natural Alternatives International and Dermata Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Dermata Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -6.90%. Dermata Therapeutics' return on equity of -166.66% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-6.90%	-2,383.34%	-24.43%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mannatech has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Mannatech. MarketBeat recorded 3 mentions for Dermata Therapeutics and 1 mentions for Mannatech. Mannatech's average media sentiment score of 1.87 beat Dermata Therapeutics' score of 0.47 indicating that Mannatech is being referred to more favorably in the media.

Company	Overall Sentiment
Mannatech	Very Positive
Dermata Therapeutics	Neutral

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 47.5% of Mannatech shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dermata Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$107.36M	0.12	-$15.21M	-$3.91	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

Summary

Mannatech beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Agape ATP?

Agape ATP (NASDAQ:ATPC) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Dermata Therapeutics has a net margin of 0.00% compared to Agape ATP's net margin of -85.94%. Agape ATP's return on equity of -5.47% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agape ATP	-85.94%	-5.47%	-4.94%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Agape ATP has higher revenue and earnings than Dermata Therapeutics. Agape ATP is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agape ATP	$1.52M	1.57	-$2.28M	-$0.74	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 2.0% of Agape ATP shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Agape ATP. MarketBeat recorded 3 mentions for Dermata Therapeutics and 1 mentions for Agape ATP. Agape ATP's average media sentiment score of 1.87 beat Dermata Therapeutics' score of 0.47 indicating that Agape ATP is being referred to more favorably in the media.

Company	Overall Sentiment
Agape ATP	Very Positive
Dermata Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agape ATP	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Agape ATP has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

Agape ATP and Dermata Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$5.39M	$23.56B	$15.93B	$12.90B
Dividend Yield	N/A	4.26%	3.20%	11.28%
P/E Ratio	-0.31	19.50	13.61	25.45
Price / Sales	N/A	13.53	263,621.83	75.83
Price / Cash	N/A	29.09	57.57	53.00
Price / Book	1.54	2.97	4.47	6.14
Net Income	-$7.56M	$1.13B	$838.96M	$348.86M
7 Day Performance	-5.63%	1.14%	1.43%	-0.80%
1 Month Performance	13.56%	3.50%	0.66%	4.13%
1 Year Performance	-76.66%	-17.86%	12.81%	15.17%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	0.3155 of 5 stars	$1.34 -8.2%	N/A	-76.7%	$5.39M	N/A	N/A	8	Short Interest Increase
DSY Big Tree Cloud	0.7174 of 5 stars	$4.11 -1.2%	N/A	-81.5%	$19.52M	$2.56M	N/A	82	News Coverage Short Interest Increase Gap Up
NHTC Natural Health Trends	1.3007 of 5 stars	$1.72 -2.3%	N/A	-63.6%	$14.76M	$39.78M	N/A	140	News Coverage Positive News Gap Down
NAII Natural Alternatives International	1.0251 of 5 stars	$2.10 -3.2%	N/A	-44.3%	$13.19M	$129.86M	N/A	290	News Coverage
MTEX Mannatech	0.7629 of 5 stars	$6.80 +5.4%	N/A	-26.8%	$13.12M	$108.04M	N/A	250	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, NHTC, NAII, MTEX, and ATPC

How does Dermata Therapeutics compare to Big Tree Cloud?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Summary

How does Dermata Therapeutics compare to Mannatech?

Summary

How does Dermata Therapeutics compare to Agape ATP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, NHTC, NAII, MTEX, and ATPC

How does Dermata Therapeutics compare to Big Tree Cloud?

Does the media prefer DSY or DRMA?

Is DSY or DRMA more profitable?

Which has better earnings & valuation, DSY or DRMA?

Do institutionals & insiders hold more shares of DSY or DRMA?

Do analysts rate DSY or DRMA?

Which has more volatility & risk, DSY or DRMA?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Which has more volatility and risk, DRMA or NHTC?

Which has stronger valuation & earnings, DRMA or NHTC?

Do insiders & institutionals hold more shares of DRMA or NHTC?

Does the media refer more to DRMA or NHTC?

Do analysts prefer DRMA or NHTC?

Is DRMA or NHTC more profitable?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Which has more volatility & risk, NAII or DRMA?

Does the media refer more to NAII or DRMA?

Do analysts rate NAII or DRMA?

Do institutionals & insiders believe in NAII or DRMA?

Which has preferable earnings and valuation, NAII or DRMA?

Is NAII or DRMA more profitable?

Summary

How does Dermata Therapeutics compare to Mannatech?

Is MTEX or DRMA more profitable?

Do analysts recommend MTEX or DRMA?

Which has more risk & volatility, MTEX or DRMA?

Does the media favor MTEX or DRMA?

Do institutionals & insiders hold more shares of MTEX or DRMA?

Which has higher valuation and earnings, MTEX or DRMA?

Summary

How does Dermata Therapeutics compare to Agape ATP?

Is ATPC or DRMA more profitable?

Which has better valuation & earnings, ATPC or DRMA?

Do institutionals and insiders have more ownership in ATPC or DRMA?

Does the media refer more to ATPC or DRMA?

Do analysts rate ATPC or DRMA?

Which has more risk & volatility, ATPC or DRMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools